Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver

Table 3

Summary of dose volume constraints for 3-fraction SABR regimen.

Organs at risk	Wulf et al. [15]	Hoyer et al. [24]	Timmerman [30]	Rusthoven et al. [25]	QUANTEC [31]
Liver	𝐷30% < 21 Gy; 𝐷50% < 15 Gy	700 mL < 15 Gy	700 mL < 17 Gy	700 mL < 15 Gy	700 mL ≤ 15 Gy; 𝐷mean < 15 Gy
Esophagus	𝐷5mL < 21 Gy	𝐷1mL < 21 Gy	𝐷5mL < 21 Gy,; 𝐷max < 27 Gy	NA	NA
Stomach	𝐷5mL < 21 Gy	𝐷1mL < 21 Gy	𝐷10mL < 21 Gy; 𝐷max < 24 Gy	𝐷max ≤ 30 Gy	𝐷max < 30 Gy
Bowel	𝐷5mL < 21 Gy	𝐷1mL < 21 Gy	𝐷5mL < 16 Gy; 𝐷max < 24 Gy	𝐷max ≤ 30 Gy	𝐷max < 30 Gy
Kidney	NA	Total kidney; 𝐷35% < 15 Gy	Total kidney; 200 mL < 14.4 Gy	Total kidney; 𝐷35% < 15 Gy	NA
Spinal cord	NA	𝐷max < 18 Gy	𝐷0.25mL < 18 Gy; 𝐷max < 22 Gy	𝐷max ≤ 18 Gy	𝐷max ≤ 20 Gy
Heart	𝐷5mL < 21 Gy	𝐷1mL < 30 Gy	𝐷15mL < 24 Gy; 𝐷max < 30 Gy	NA	NA

SABR: stereotactic ablative radiotherapy; QUANTEC: Quantitative Analyses of Normal Tissue Effects in the Clinic; NA: not available; 𝐷_𝑥%: dose to 𝑥%; 𝐷_𝑥mL: dose to 𝑥mL; 𝐷_max: maximum point dose; 𝐷_mean: mean dose.